Mark Reding, M.D.

Dr. Reding is an Assistant Professor in the Division of Hematology, Oncology, and Transplantation.  He received his M.D. in 1992 from the University of Minnesota. He also completed residency training in Internal Medicine and subspecialty training in Hematology/Oncology at the University of Minnesota.  He is board certified in both Hematology and Medical Oncology.

Dr. Reding’s clinical interest is the treatment of malignant and nonmalignant hematologic disorders, with particular emphasis on disorders of thrombosis and hemostasis, including hemophilia.  His current research efforts focus on the immune response to factor VIII, the cellular mechanisms involved in the synthesis of factor VIII inhibitors, and the immunologic consequences of gene therapy.

Selected Publications

Reding MT, Hibbs JR, Morrison VA, Swaim WR, Filice GA.  Diagnosis and outcome of 100 consecutive patients with extreme granulocytic leukocytosis.  Am J Med 1998; 104: 12-16.

Reding MT, Conti-Fine BM, Key NS.  Pathophysiology and treatment of factor VIII inhibitors.  Turk J Haematol 1998; 15:  149-156.

Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Key NS, Conti-Fine BM.  CD4+ T Cell response to factor VIII in hemophilia A, Acquired hemophilia, and healthy subjects.  Thromb Haemost (suppl. 1999 State of the Art, L. Hoyer (ed.) 1999; 82:  509-515.

Reding, MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Key NS, Conti-Fine BM. CD4+ T Cells specific for factor VIII as a target for specific suppression of inhibitor production.  In: Monroe D (ed.). Hemophilia Care in the New Millenium.  Kluwer Academic/Plenum:  New York, 2000, pp. 119-134.

Reding, MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Christie BA, Key NS, Conti-Fine BM. Sensitization of CD4+ T cells to coagulation factor VIII:  Response in congenital and acquired hemophilia patients and in healthy subjects.  Thromb Haemost 2000; 84:  643-652.

Wu H, Reding MT, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW, Conti-Fine BM.  Mechanism of the immune response to human factor VIII in murine hemophilia A.  Thromb Haemost 2001; 85:  125-133.

Ashrani AA, Reding MT, Greeno EW, Shet A, Key NS.  Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia.  Haemophilia 2002; 8:56-58.

Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM.  Distribution of Th1- and Th2-induced anti-factor VIII subclasses in congenital and acquired hemophilia patients.  Thromb Haemost 2002; 88:568-575.

Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM.  Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII.  J Thromb Haemost 2003; 1:1777-1784.

Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM.  Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII.  J Thromb Haemost 2004; 2:1385-1394.

Ashrani AA, Reding MT, Shet A, Osip J, Humar A, Lake JR, Key NS. Successful liver transplantation in a patient with severe haemophilia A and a high-titre factor VIII inhibitor.  Haemophilia. 2004; 10:735-7.